Market Research Logo

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Metastatic Breast Cancer
Dec 08, 2017: Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Dec 07, 2017: Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival
Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)
Dec 05, 2017: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium
Dec 05, 2017: New Scientific Publication Supports Agilvax’s Novel Immunotherapy Development for Metastatic Breast Cancer
Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit
Nov 30, 2017: New and Updated Data for Merck’s KEYTRUDA (pembrolizumab) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)
Nov 30, 2017: Updated Data on LYNPARZA (olaparib) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)
Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS
Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium
Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017
Nov 06, 2017: Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer
Oct 31, 2017: Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Oct 31, 2017: Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer
Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum
Oct 06, 2017: Lilly MONARCH 3 Study Published In Journal Of Clinical Oncology Demonstrates Benefit Of Verzenio (Abemaciclib) Plus NSAI In Advanced Breast Cancer
Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program
Sep 22, 2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017*
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017*
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
List of Figures
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017*
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017*
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
GlobalData Methodology

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, “Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017 provides an overview of Metastatic Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;